{
  "context": {
    "rules": [
      "Rule1: Provided that plant1 has medicinal property substance1, then substance1 passes toxicity test.",
      "Rule2: If trial phase1 is completed for trial1, then in case patient consent is not obtained for trial1, it follows that trial ethics are not approved for trial1.",
      "Rule3: Under the condition that positive results are achieved in trial1, trial phase1 is completed for trial1.",
      "Rule4: Either positive results are achieved in trial1 or safety standards are met in trial1.",
      "Rule5: If regulatory review is passed for trial1, then regulatory submission is filed for trial1.",
      "Rule6: Provided that marketing approval is granted for trial1, regulatory review is passed for trial1.",
      "Rule7: Whenever a manufacturing partner is secured for substance1, then if cost-effective production is achieved for substance1, medicine is developed for substance1.",
      "Rule8: Under the condition that a production facility is built for substance1, then provided that cost-effective production is achieved for substance1, medicine is developed for substance1.",
      "Rule9: Provided that investment is secured for project1, venture capital is invested in project1.",
      "Rule10: Either investment is secured for project1 or a government grant is awarded to project1.",
      "Rule11: Whenever a government grant is awarded to project1, a production facility is built for substance1.",
      "Rule12: If conflicting study results exist for substance1, then consistent efficacy data exists for substance1.",
      "Rule13: Provided that conflicting study results exist for substance1, it is not the case that consistent efficacy data exists for substance1.",
      "Rule14: Either conflicting study results exist for substance1 or if venture capital is invested in project1, then a manufacturing partner is secured for substance1.",
      "Rule15: A control group is established in trial1 or patient dropout occurs in trial1.",
      "Rule16: If patient dropout occurs in trial1, then patient consent is obtained for trial1.",
      "Rule17: Provided that blinding is maintained in trial1, placebo effect is detected in trial1.",
      "Rule18: Traditional use is recorded for plant1 or a scientific study is published for plant1.",
      "Rule19: If the data monitoring committee approves trial1, then in case it is not true that if a control group is established in trial1 then blinding is maintained in trial1, statistical significance is achieved in trial1.",
      "Rule20: The data monitoring committee approves trial1 or an independent statistical analysis is performed on trial1.",
      "Rule21: Supposing that peer review is passed for trial1, then if it is not true that whenever a control group is established in trial1 blinding is maintained in trial1, statistical significance is achieved in trial1.",
      "Rule22: Publication is rejected for study1 or if an independent statistical analysis is performed on trial1, then peer review is passed for trial1.",
      "Rule23: If safety monitoring is implemented for trial1, then a patient surveillance system is in place for trial1.",
      "Rule24: Given that a risk management plan is approved for trial1, adverse effects are not reported in trial1.",
      "Rule25: If an interim analysis is conducted for trial1, then in case it is not true that if safety standards are met in trial1 then trial phase1 is completed for trial1, regulatory review is passed for trial1.",
      "Rule26: An interim analysis is conducted for trial1 or a data safety review is performed for trial1.",
      "Rule27: Provided that a scientific study is published for plant1, then if substance1 passes toxicity test, medicine is developed for substance1.",
      "Rule28: If manufacturing quality is controlled for substance1, then provided that a data safety review is performed for trial1, then if it is not true that safety standards being met in trial1 leads to trial phase1 being completed for trial1, regulatory review is passed for trial1.",
      "Rule29: Whenever GMP certification is obtained by facility1, manufacturing quality is controlled for substance1.",
      "Rule30: Either GMP certification is obtained by facility1 or a quality assurance system exists for substance1.",
      "Rule31: Provided that contamination is detected in substance1, a batch passes quality check for substance1.",
      "Rule32: Under the condition that stability testing is completed for substance1, then if contamination is detected in substance1, a batch does not pass quality check for substance1.",
      "Rule33: Shelf life is established for substance1 or stability testing is completed for substance1.",
      "Rule34: Packaging validation is done for substance1 or shelf life is not established for substance1.",
      "Rule35: Whenever clinical trial is approved for substance1, then if substance1 passes toxicity test, medicine is developed for substance1.",
      "Rule36: Provided that extraction method is optimized for plant1, clinical trial is approved for substance1.",
      "Rule37: Research funding is approved for project1 or if traditional use is recorded for plant1, then extraction method is optimized for plant1.",
      "Rule38: Laboratory space is available at facility1 or research funding is not approved for project1.",
      "Rule39: If patient consent is obtained for trial1, then medicine is developed for substance1.",
      "Rule40: Supposing that safety standards being met in trial1 does not lead to trial phase1 being completed for trial1, marketing approval is granted for trial1.",
      "Rule41: Under the condition that it is not true that whenever safety standards are met in trial1 trial phase1 is completed for trial1, regulatory submission is not filed for trial1.",
      "Rule42: Provided that it is not true that a patient surveillance system being in place for trial1 implies a risk management plan is approved for trial1, an emergency protocol is activated for trial1.",
      "Rule43: Whenever it is not the case that if a patient surveillance system is in place for trial1 then a risk management plan is approved for trial1, an emergency protocol is not activated for trial1.",
      "Rule44: Supposing that it is not true that a quality assurance system existing for substance1 leads to manufacturing quality being controlled for substance1, contamination is detected in substance1.",
      "Rule45: If it is not the case that if patient consent is not obtained for trial1 then trial ethics are not approved for trial1, adverse effects are reported in trial1.",
      "Rule46: Under the condition that it is not true that provided patient consent is not obtained for trial1 trial ethics are not approved for trial1, safety monitoring is implemented for trial1.",
      "Rule47: If patient consent is not obtained for trial1, then trial ethics are approved for trial1."
    ],
    "facts": [
      "Fact1: Plant1 has medicinal property substance1.",
      "Fact2: Cost-effective production is achieved for substance1.",
      "Fact3: It is not the case that placebo effect is detected in trial1.",
      "Fact4: Statistical significance is not achieved in trial1.",
      "Fact5: Publication is not rejected for study1.",
      "Fact6: Packaging validation is not done for substance1.",
      "Fact7: Laboratory space is not available at facility1."
    ]
  },
  "question": "Medicine is developed for substance1."
}